|
Feb 27
|
UroGen Pharma to Report Fourth Quarter and Full-Year 2024 Financial Results on Monday, March 10, 2025
|
|
Feb 25
|
Is UroGen Pharma Ltd. (URGN) the Best Small-Cap Growth Stock to Buy Now?
|
|
Feb 24
|
UroGen Pharma to Present at TD Cowen 45th Annual Health Care Conference
|
|
Feb 21
|
UroGen acquires IconOVir’s oncolytic virus assets
|
|
Feb 20
|
UroGen Advances Long-Term Growth Strategy by Acquiring a Next-Generation Investigational Oncolytic Virus (ICVB-1042) and Announces Multiple Strategic Research Collaborations
|
|
Feb 14
|
UroGen Announces Results from Subgroup Analyses of the Pivotal ENVISION Trial Evaluating Impact of Baseline Tumor Burden and Focality on Response to UGN-102
|
|
Feb 12
|
Data from a Long-Term Follow-up Study to the OLYMPUS Trial that Shows a Median Duration of Response of Nearly Four Years in Patients Achieving Complete Response with JELMYTO Published in The Journal of Urology
|
|
Dec 31
|
Breakeven On The Horizon For UroGen Pharma Ltd. (NASDAQ:URGN)
|
|
Oct 9
|
UroGen Pharma Ltd (URGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial ...
|
|
Oct 9
|
UroGen Appoints Chris Degnan as Chief Financial Officer
|
|
Oct 3
|
UroGen begins subject dosing in Phase III bladder cancer drug trial
|
|
Oct 2
|
First Patient Dosed in Phase 3 Clinical Trial of UGN-103, a Next Generation Mitomycin-Based Formulation in Development for the Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
|
|
Aug 29
|
UroGen Pharma to Present at Upcoming Investor Conferences
|
|
Aug 16
|
UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88
|
|
Jun 27
|
UroGen Pharma Stock Earns 91 RS Rating
|
|
Jun 18
|
UroGen Pharma Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jun 17
|
UroGen Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
|
|
Jun 17
|
Urogen Pharma (URGN) Surges 9.7%: Is This an Indication of Further Gains?
|
|
Jun 13
|
UroGen Catapults On 'Unprecedented' Results For Gel-Based Cancer Drug
|
|
Jun 13
|
UroGen Announces Unprecedented 82.3% Duration of Response at 12 Months in the ENVISION Trial Investigating UGN-102 as Potentially the First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC
|